Nasal application of the galantamine pro-drug memogain slows down plaque deposition and ameliorates behavior in 5X familial Alzheimer's disease mice

Journal of Alzheimer's Disease

Volumn 46, Issue 1, 2015, Pages 123-136

  Bhattacharya, Soumee ^a   Maelicke, Alfred ^b   Montag, Dirk ^a  

^a LEIBNIZ INSTITUTE FOR NEUROBIOLOGY   (Germany)

^b Galantos Pharma GmbH   (Germany)

Author keywords

Acetylcholinesterase inhibitor; Alzheimer's disease; amyloid plaques; galantamine; nasal application; nicotinic enhancer

Indexed keywords

AMYLOID BETA PROTEIN; GALANTAMINE; MEMOGAIN; PRODRUG; UNCLASSIFIED DRUG; AMYLOID PRECURSOR PROTEIN; CHOLINESTERASE INHIBITOR; PRESENILIN 1; PSEN1 PROTEIN, HUMAN;

5XFAD MOUSE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC DRUG ADMINISTRATION; CONDITIONING; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; ENTORHINAL CORTEX; FEMALE; GENDER; HIPPOCAMPUS; LIGHT-DARK TEST; MALE; MOUSE; NONHUMAN; OPEN FIELD TEST; PRIORITY JOURNAL; SCOPOLAMINE-INDUCED AMNESIA; SENILE PLAQUE; ALZHEIMER DISEASE; ANALOGS AND DERIVATIVES; ANIMAL; ANIMAL BEHAVIOR; C57BL MOUSE; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; FEAR; GENETICS; HUMAN; INTRANASAL DRUG ADMINISTRATION; METABOLISM; MOTOR ACTIVITY; MUSCLE STRENGTH; MUTATION; PHYSIOLOGY; PLAQUE, AMYLOID; TRANSGENIC MOUSE;

ADMINISTRATION, INTRANASAL; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BEHAVIOR, ANIMAL; CHOLINESTERASE INHIBITORS; CONDITIONING (PSYCHOLOGY); DISEASE MODELS, ANIMAL; FEAR; GALANTAMINE; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MOTOR ACTIVITY; MUSCLE STRENGTH; MUTATION; PLAQUE, AMYLOID; PRESENILIN-1; PRODRUGS;

EID: 84929334915     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-142421     Document Type: Article

References (55)

1. Patel L, Grossberg GT (2011) Combination therapy for Alzheimer's disease. Drugs Aging 28, 539-546.
2. Maelicke A, Smaochocki M, Jostock R, Fehrenbacher A, Ludwig J, Albuquerque EX, Zerlin M (2001) Allosteric sensi-tization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer's disease.Biol Psychiatry49, 279-288.
3. Lilienfeld S (2002) Galantamine-a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease. CNS Drug Rev 8, 159-176.
4. Court JA, Perry EK (1994) CNS nicotine receptors. Possible therapeutic targets in neurodegenerative disorders. CNS Drugs 2, 216-233.
5. Peng X, Gerzanich V, Anand R, Wang F, Lindstrom J (1997) Chronic nicotine treatment up-regulates alpha3 and alpha7 acetylcholine receptor subtypes expressed by the human neu-roblastoma cell line SH-SY5Y. Mol Pharmacol 51, 776-784.
6. Kihara T, Shimohama S, Urushitani M, Sawada H, Kimura J, Kume T, Maeda T, Akaike A (1998) Stimulation of alpha4beta2 nicotinic acetylcholine receptors inhibits beta-amyloid toxicity. Brain Res 792, 331-334.
7. Wilcock G, Howe I, Coles H, Lilienfeld S, Truyen L, Zhu Y, Bullock R, Kershaw P (2003) A long-term comparison of galantamine and donepezil in the treatment of Alzheimer's disease. Drugs Aging 20, 777-789.
8. Lenzken SC, Lanni C, Govoni S, Lucchelli A, Schettini G, Racchi M (2007) Nicotinic component of galantamine in the regulation of amyloid precursor protein processing. Chem Biol Interact 165, 138-145.
9. Villarroya M, Garcia AG, Marco-Contelles J, Lopez MG (2007) An update on the pharmacology of galantamine. Expert Opin Investig Drugs 16, 1987-1998.
10. Matharu B, Gibson G, Parsons R, Huckerby TN, Moore SA, Cooper LJ, Millichamp R, Allsop D, Austen B (2009) Galantamine inhibits beta-amyloid aggregation and cytotoxicity. J Neurol Sci 280, 49-58.
11. Takata K, Kitamura Y, Saeki M, Terada M, Kagitani S, Kita-mura R, Fujikawa Y, Maelicke A, Tomimoto H, Taniguchi T, Shimohama S (2010) Galantamine induced amyloid-β clearance mediated via stimulation of microglial nicotinic acetylcholine receptors. J Biol Chem 285, 40180-40191.
12. Wallin AK, Wattmo C, Minthon L (2011) Galantamine treatment in Alzheimer's disease: Response and long-term outcome in aroutine clinical setting. NeuropsychiatrDis Treat 7, 565-576.
13. Kavanagh S, Gaudig M, Van Baelen B, Adami M, Delgado A, Guzman C, Jedenius E, Schäuble B (2011) Galantamine and behavior in Alzheimer disease: Analysis of four trials. Acta Neurol Scand 124, 302-308.
14. Keller C, Kadir A, Forsberg A, Porras O, Nordberg A (2011) Long-term effects of galantamine treatment on brain functional activities as measured by PET in Alzheimer's disease patients. J Alzheimers Dis 24, 109-123.
15. Bhattacharya S, Haertel C, Maelicke A, Montag D (2014) Galantamine slows down plaque formation and behavioral decline in the 5XFAD mouse model of Alzheimer's disease. PLoS One 9, 89454.
16. Maelicke A, Hoeffle-Maas A, Ludwig J, Maus A, Samochocki M, Jordis U, Koepke AKE (2010) Memogain is a galantamine pro-drug having dramatically reduced adverse effects and enhanced efficacy. J Mol Neurosci 40, 135-137.
17. Leonard AK, Sileno AP, MacEvilly C, Foerder CA, Quay SC, Costantino HR (2005) Development of a novel high-concentration galantamine formulation suitable for intranasal delivery. J Pharm Sci 94, 1736-1746.
18. Costantino HR, Leonard AK, Brandt G, Johnson PH, Quay SC (2008) Intranasal administration of acetylcholinesterase inhibitors. BMC Neurosci 9(Suppl 3), S6.
19. Park CW, Son DD, Kim JY, Oh TO, Ha JM, Rhee YS, Park ES (2012) Investigation of formulation factors affecting in vitro and in vivo characteristics of a galantamine transdermal system. Int J Pharm 436, 32-40.
20. Oakley H, Cole SL, Logan S, Maus E, Shao P, Craft J, Guillozet-Bongaarts A, Ohno M, Disterhoft J, Van Eldik L, Berry R, Vassar R (2006) Intraneuronal β-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: Potential factors in amyloid plaque formation. J Neurosci 26, 10129-10140.
21. Comery TA, Martone RL, Aschmies S, Atchison KP, Diamantidis G, Gong X, Zhou H, Kreft AF, Pangalos MN, Sonnenberg-Reines J, Jacobsen JS, Marquis KL (2005) Acute gamma-secretase inhibition improves contextual fear conditioning in the Tg2576 mouse model of Alzheimer's disease. J Neurosci 25, 8898-8902.
22. Jacobsen JS, Wu CC, Redwine JM, Comery TA, Arias R, Bowlby M, Martone R, Morrison JH, Pangalos MN, Reinhart PH, Bloom FE (2006) Early onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease. Proc Natl AcadSci USA 103, 5161-5166.
23. Schilling S, Zeitschel U, Hoffmann T, Heiser U, Francke M, Kehlen A, Holzer M, Hutter-Paier B, Prokesch M, Windisch M, Lindner C, Rudolph T, Reuter G, Cynis H, Montag D, Demuth HU, Rossner S (2008) Glutaminyl cyclase inhibition attenuates pyroglutamate Aβ and Alzheimer's disease-like pathology in vivo. Nat Med 14, 1106-1111.
24. Sun A, Nguyen XV, Bing G (2002) Comparative analysis of an improved thioflavin-s stain, Gallyas silver stain, and immunohistochemistry for neurofibrillary tangle demonstration on the same sections. J Histochem Cytochem 50, 463-472.
25. Loy C, Schneider L (2006) Galantamine for Alzheimer's disease and mild cognitive impairment. Cochrane Database Syst Rev, CD001747.
26. Burns A, Bernabei R, Bullock R, Cruz Jentoft AJ, Frölich L, Hock C, Raivio M, Triau E, Vandewoude M, Wimo A, Came E, Van Baelen B, Hammond GL, van Oene JC, Schwalen S (2009) Safety and efficacy of galantamine (Reminyl) in severe Alzheimer's disease (the SERAD study): A randomised, placebo-controlled, double-blind trial. Lancet Neurol 8, 39-47.
27. Seltzer B (2010) Galantamine-ER for the treatment of mild-to-moderate Alzheimer's disease. Clin Interv Aging 5, 1-6.
28. Cicinelli E, Cignarelli M, Petruzzi D, Matteo MG, Ruccia C, Schonauer LM (1996) Nasal spray vs. oral administration of bromocriptine: pharmacology and effect on serum prolactin in puerperal women. J Endocrinol Invest 19, 427-432.
29. Illum L, Watts P, Fisher AN, Hinchcliffe M, Norbury H, Jabbal-Gill I, Nankervis R, Davis SS (2002) Intranasal delivery of morphine. J Pharmacol Exp Ther301, 391-400.
30. Costantino HR, Illum L, Brandt G, Johnson PH, Quay SC (2007) Intranasal delivery: Physicochemical and therapeutic aspects. Int J Pharm 337, 1-24.
31. Kays Leonard A, Sileno PA, Brandt GC, Foerder CA, Quay SC, Costantino HR (2007) In vitro formulation optimization of intranasal galantamine leading to enhanced bioavailability and reduced emetic response in vivo. Int J Pharm 335, 138-146.
32. Bartus RT (1978) Evidence for a direct cholinergic involvement in the scopolamine-induced amnesia in monkeys: Effects of concurrent administration of physostigmine and methylphenidate with scopolamine. Pharmacol Biochem Behav 9, 833-836.
33. Taffe MA, Weed MR, Gold LH (1999) Scopolamine alters rhesus monkey performance on a novel neuropsychological test battery. Brain Res Cogn Brain Res 8, 203-212.
34. Bejar C, Wang RH, Weinstock M (1999) Effect of rivastig-mine on scopolamine-induced memory impairment in rats. Eur J Pharmacol 383, 231-240.
35. van der Staay FJ, Bouger PC (2005) Effects of the cholinesterase inhibitors donepezil and metrifonate on scopolamine-induced impairments in the spatial cone field orientation task in rats. Behav Brain Res 156, 1-10.
36. Rupniak NM, Tye SJ, Field MJ (1997) Enhanced performance of spatial and visual recognition memory tasks by the selective acetylcholinesterase inhibitor E2020 in rhesus monkeys. Psychopharmacology 131, 406-410.
37. de Bruin N, Pouzet B (2006) Beneficial effects of galan-tamine on performance in the object recognition task in Swiss mice: Deficits induced by scopolamine and by prolonging the retention interval. Pharmacol Biochem Behav 85, 253-260.
38. Janus C, Westaway D (2001) Transgenic mouse models of Alzheimer's disease. Physiol Behav 73, 873-886.
39. Hsiao KK, Borchelt DR, Olson K, Johannsdottir R, Kitt C, Yunis W, Xu S, Eckman C, Younkin S, Price D, Iadecola C, Clark HB, Carlson G (1995) Age-related CNS disorder and early death in transgenic FVB/N mice overexpressing Alzheimer amyloid precursor proteins. Neuron 15, 1203-1218.
40. Moechars D, Dewachter I, Lorent K, Reversé D, Baekelandt V, Naidu A, Tesseur I, Spittaels K, Haute CV, Checler F, Godaux E, Cordell B, Van Leuven F (1999) Early pheno-typic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain. J Biol Chem 274, 6483-6492.
41. Guo Q, Li H, Cole AL, Hur JY, Li Y, Zheng H (2013) Modeling Alzheimer's disease in mouse without mutant protein overexpression: Cooperative and Independent effects of Aβ and tau. PloS One 8, e80706.
42. Ferretti L, McCurry SM, Logsdon R, Gibbons L, Teri L (2001) Anxiety and Alzheimer's disease. J Geriatr Psychiatry Neurol 14, 52-58.
43. Hwang TJ, Masterman DL, Ortiz F, Fairbanks LA, Cummings JL (2004) Mild cognitive impairment is associated with characteristic neuropsychiatric symptoms. Alzheimer Dis Assoc Disord 18, 17-21.
44. Disterhoft JF, Oh MM (2006) Pharmacological and molecular enhancement of learning in aging and Alzheimer's disease. J Physiol 99, 180-192.
45. Ringman JM, Cummings JL (1999) Metrifonate (Trichlor-fon): A review of the pharmacology, pharmacokinetics and clinical experience with a new acetylcholinesterase inhibitor for Alzheimer's disease. Expert Opin Investig Drugs 8, 463-471.
46. Mineur YS, Obayemi A, Wigestrand MB, Fote GM, Calarco CA, Li AM, Picciotto MR (2013) Cholinergic signaling in the hippocampus regulates social stress resilience and anxiety-and depression-like behavior. Proc Natl Acad Sci USA 110, 3573-3578.
47. Barnett JH, Lewis L, Blackwell AD, Taylor M (2014) Early intervention in Alzheimer's disease: A health economic study of the effects of diagnostic timing. BMC Neurol 14, 101.
48. Budd D, Burns LC, Guo Z, L'Italien G, Lapuerta P (2011) Impact of early intervention and disease modifcation in patients with predementia Alzheimer's disease: A Markov model simulation. Clinicoecon Outcomes Res 3, 189-195.
49. Rao PP, Mohamed T, Osman W (2013) Investigating the binding interactions of galantamine with β-amyloid peptide. Bioorg Med Chem Lett 23, 239-243.
50. Singh M, Kaur M, Kukreja H, Chugh R, Silakari O, Singh D (2013) Acetylcholinesterase inhibitors as Alzheimer therapy: From nerve toxins to neuroprotection. Eur J Med Chem 70, 165-188.
51. Lecoutey C, Hedou D, Freret T, Giannoni P, Gaven F, Since M, Bouet V, Ballandonne C, Corvaisier S, Malzert Fréon A, Mignani S, Cresteil T, Boulouard M, Claeysen S, Rochais C, Dallemagne P (2014) Design of donecopride, a dual serotonin subtype 4 receptor agonist/acetylcholinesterase inhibitor with potential interest for Alzheimer's disease treatment. Proc Natl Acad Sci USA 111, E3825-E3830.
52. Demattos RB, Lu J, Tang Y, Racke MM, Delong CA, Tzaferis JA, Hole JT, Forster BM, McDonnell PC, Liu F, Kinley RD, Jordan WH, Hutton ML (2012) A plaque-specific antibody clears existing β-amyloid plaques in Alzheimer's disease mice. Neuron 76, 908-920.
53. Jucker M, Walker LC (2013) Self-propagation of pathogenic protein aggregates in neurodegenerative diseases. Nature 501, 45-51.
54. Chételat G, Villemagne VL, Villain N, Jones G, Ellis KA, Ames D, Martins RN, Masters CL, Rowe CC (2012) Accelerated cortical atrophy in cognitively normal elderly with high β-amyloid deposition. Neurology 78, 477-484.
55. Becker JA, Hedden T, Carmasin J, Maye J, Rentz DM, Putcha D, Fischl B, Greve DN, Marshall GA, Salloway S, Marks D, Buckner RL, Sperling RA, Johnson KA (2011) Amyloid-β associated cortical thinning in clinically normal elderly. Ann Neurol 69, 1032-1042.